Angioedema of the tongue with an unfamiliar final diagnosis DUPE

Annals of Allergy, Asthma & Immunology

April Volume 114, Issue 4, Pages 269-272 MOC-CME Review

Overall Purpose
Participants will be able to demonstrate increased knowledge of the clinical treatment of allergy/asthma/immunology and how new information can be applied to their own practices

Accreditation:The American College of Allergy, Asthma & Immunology (ACAAI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation:The American College of Allergy, Asthma & Immunology (ACAAI) designates this journal-based CME activity for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


Planning Committee Members
Gregory V. Marcotte, MD, (Author)
John J. Oppenheimer, MD (Clinical Series Editor)
Mitchell H. Grayson, MD (CME Series Editor, Deputy Editor)
Gailen D. Marshall, Jr., MD, PhD (Editor-in-Chief)   

Target Audience

Physicians involved in providing patient care in the field of allergy/asthma/immunology

Learning Objectives

At the conclusion of this activity, participants should be able to:
Describe the clinical and pathophysiologic presentation of angioedema as well as that of amyloidosis
Recognize the need for and symptoms of deep brain stimulators

Additional information
Disclosure: 

M.H. Grayson has received research grants from Children's Research Institute/Children's Hospital of Wisconsin, Merck, National Institutes of Health (NIH), and Polyphor. G.D. Marshall has received research grants from Amgen, AstraZeneca, Health Resources and Services Administration (HRSA) and National Institutes of Health (NIH). J.J. Oppenheimer has been a consultant/advisor for AstraZeneca, GlaxoSmithKline, Meda, Mylan, and Sunovion; has received research grants from AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline and Novartis. M.W. LaSorda and G.V. Marcotte have no financial relationships to disclose. Reviewers and Education/Editorial staff have no relevant financial relationships to disclose. Any unapproved/investigative uses of therapeutic agents/devices discussed are to be appropriately noted.

Course summary
Available credit: 
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Attendance
  • 1.00 MOC
Course opens: 
04/01/2015
Course expires: 
03/31/2017
Cost:
$0.00
Mark William LaSorda, Gregory Vincent Marcotte

    Available Credit

    • 1.00 AMA PRA Category 1 Credit™
    • 1.00 Attendance
    • 1.00 MOC

    Accreditation Period

    Course opens: 
    04/01/2015
    Course expires: 
    03/31/2017

    Price

    Cost:
    $0.00
    Please login or create an account to take this course.